- Smilow Cancer Hospital at Yale New Haven35 Park StreetNew Haven, CT 06511
Adriana Matutino Kahn, MD
Medical Oncology
Telehealth is available
Patient type treated
Adult
Accepting new patients
Yes
Referral required
Not Applicable
Board Certified in
Internal Medicine
Titles
- Assistant Professor of Medicine (Medical Oncology)
Education & Training
- Medical Oncology FellowYale School of Medicine (2023)
- Internal Medicine ResidentUniversity of Connecticut (2021)
- Breast Cancer FellowUniversity of Calgary (2018)
- Medical Oncology FellowUniversidade de São Paulo (2016)
- Internal Medicine ResidentUniversidade de São Paulo (2013)
- MDUniversidade Federal da Bahia (2010)
Languages Spoken
- English
- Português (Portuguese)
Additional Information
Honors & Recognitions
- Robert A. Winn Diversity in Clinical Trials Career Development Award: American Association of Cancer Research (2023)
- Young Investigator Award: American Society of Clinical Oncology (ASCO) (2023)
Publications
- Foldi J, Kahn A, Silber A, Qing T, Reisenbichler E, Fischbach N, Persico J, Adelson K, Katoch A, Chagpar A, Park T, Blanchard A, Blenman K, Rimm DL, Pusztai L. Clinical Outcomes and Immune Markers by Race in a Phase I/II Clinical Trial of Durvalumab Concomitant with Neoadjuvant Chemotherapy in Early-Stage TNBC. Clinical Cancer Research 2022, 28: 3720-3728. PMID: 35903931, PMCID: PMC9444984, DOI: 10.1158/1078-0432.ccr-22-0862.
- Silva S, Pereira A, Marta G, de Barros Lima K, de Freitas T, Matutino A, de Azevedo Souza M, de Azevedo R, de Viveiros P, da Silva Lima J, Filassi J, de Andrade Carvalho H, Piato J, Mano M. Clinical impact of adjuvant radiation therapy delay after neoadjuvant chemotherapy in locally advanced breast cancer. The Breast 2017, 38: 39-44. PMID: 29223797, DOI: 10.1016/j.breast.2017.11.012.
- Shan NL, Kahn A, Pusztai L. Intratumour heterogeneity, from hypothesis to the clinic. British Journal Of Cancer 2022, 128: 459-460. PMID: 36216884, PMCID: PMC9938204, DOI: 10.1038/s41416-022-02008-w.
- Matutino A, Amaro C, Verma S. CDK4/6 inhibitors in breast cancer: beyond hormone receptor-positive HER2-negative disease. Therapeutic Advances In Medical Oncology 2018, 10: 1758835918818346. PMID: 30619511, PMCID: PMC6299331, DOI: 10.1177/1758835918818346.
- Matutino A, Lewis J, Verma S, Taylor A, Huber S, Chen G. The impact of age in the quality of life of patients diagnosed with breast cancer after curative treatment. Journal Of Clinical Oncology 2018, 36: 67-67. DOI: 10.1200/jco.2018.36.7_suppl.67.
- Kahn AM, Blenman KRM, Sonis ST, Lustberg MB. Strategies to mitigate the toxicity of cancer therapeutics. 2022, 155: 215-244. PMID: 35779875, DOI: 10.1016/bs.acr.2022.02.006.
- Matutino A, Pereira A, Kornaga E, Lupichuk S, Verma S. Comparison of clinical characteristics and survival of metastatic breast cancer patients in United States according to insurance status as compared to outcomes in Canada. Journal Of Clinical Oncology 2018, 36: e18617-e18617. DOI: 10.1200/jco.2018.36.15_suppl.e18617.
- Kahn A, Golestani R, Harigopal M, Pusztai L. Intratumor spatial heterogeneity in programmed death-ligand 1 (PD-L1) protein expression in early-stage breast cancer. Breast Cancer Research And Treatment 2023, 201: 289-298. PMID: 37378695, DOI: 10.1007/s10549-023-06977-1.
- Shalaby K, Kahn A, Silver ES, Kim MJ, Balakumaran K, Kim AS. Outcomes of acute pulmonary embolism in hospitalized patients with cancer. BMC Pulm Med 2022, 22: 11. PMID: 34986814, DOI: 10.1186/s12890-021-01808-9.
- Savard MF, Kornaga EN, Kahn AM, Lupichuk S. Survival in Women with De Novo Metastatic Breast Cancer: A Comparison of Real-World Evidence from a Publicly-Funded Canadian Province and the United States by Insurance Status. Curr Oncol 2022, 29: 383-391. PMID: 35049708, DOI: 10.3390/curroncol29010034.
- Lima G, Kahn A, Sama S, Savage J. Aseptic Meningitis as an Immune-Related Adverse Event after Pembrolizumab. Case Rep Oncol Med 2019, 2019: 7183747. PMID: 31781445, DOI: 10.1155/2019/7183747.
- Matutino A, Pereira A, Kornaga E, Lopes G, Bebb D, Verma S. Clinical characteristics and survival of lung cancer patients according to insurance status prior to and post implementation of the Affordable Care Act. Journal Of Clinical Oncology 2018, 36: e18607-e18607. DOI: 10.1200/jco.2018.36.15_suppl.e18607.
- Kornaga E, Matutino A, Pereira A, Verma S, Lupichuk S. Abstract P2-08-13: Survival in women with de novo metastatic breast cancer: Comparison of real-world evidence from publicly-funded Canadian province and the United States by insurance status. Cancer Research 2019, 79: p2-08-13-p2-08-13. DOI: 10.1158/1538-7445.sabcs18-p2-08-13.
- Matutino A, Kornaga E, Dean M, Pereira A, Bebb G. 40P Comparison of clinical characteristics and survival of lung cancer patients in a Canadian province and in the United States according to insurance status. Journal Of Thoracic Oncology 2018, 13: s22-s23. DOI: 10.1016/s1556-0864(18)30320-4.
- Matutino A, Mak M, Takahashi T, Bitton R, Nakazato D, Fraile N, Guimarães R, Gabrielli F, Vasconcelos K, de A. Carvalho H, de Castro G. Prophylactic Cranial Irradiation for Extensive-Stage Small-Cell Lung Cancer: A Retrospective Analysis. Journal Of Global Oncology 2017, 4: jgo.17.00059. PMID: 30241202, PMCID: PMC6181177, DOI: 10.1200/jgo.17.00059.
- Protásio B, Matutino A, Lage L, Santana I, Ramos R, Sabbaga J, Capareli F, Saragiotto D, Riechelmann R, Hoff P. Safety and Efficacy of a Modified FLOX Adjuvant Regimen for Patients With Stage III Colorectal Cancer Treated in the Community. Clinical Colorectal Cancer 2016, 16: 65-72. PMID: 27515842, DOI: 10.1016/j.clcc.2016.07.001.
- Silva A, Linck R, Lima J, Matutino A, Silva S, Vicentini M, Felizola M, Gagliato D, Hoff P, Mano M. Metaplastic breast cancer: A single-institution experience. Journal Of Clinical Oncology 2016, 34: e12575-e12575. DOI: 10.1200/jco.2016.34.15_suppl.e12575.
- Fraile N, Toloi D, Kurimori C, Matutino A, Codima A, Camargo V, Feher O, Munhoz R. Successful Intravascular Correction of Intratumoral Pseudoaneurysm by Erosion of the Aorta in a Patient with Thoracic Giant Cell Tumor of Bone Responding to Denosumab. Case Reports In Oncological Medicine 2015, 2015: 626741. PMID: 26600960, PMCID: PMC4639671, DOI: 10.1155/2015/626741.
- Vaisberg V, Vilas Boas M, Stephan B, Matutino A, Lima J, Mano M. Câncer de mama: efeito prognóstico da resposta patológica completa após quimioterapia neoadjuvante. Revista De Medicina 2015, 94: 31-31. DOI: 10.11606/issn.1679-9836.v94isupl.p31-31.
- Matutino A, Lima J, Silva S, Boas M, Stephan B, Van Vairsberg V, Fraile N, Barroso-Sousa R, Mano M. 1959 Neoadjuvant chemotherapy for elderly breast cancer patients. European Journal Of Cancer 2015, 51: s319. DOI: 10.1016/s0959-8049(16)30907-8.
- Lima J, Matutino A, Silva S, Silva-Junior A, Boas M, Stephan B, Van Vairsberg V, Pereira A, Barroso-Sousa R, Mano M. 1958 Correlation between body mass index and pathologic complete response after neoadjuvant chemotherapy for locally advanced breast cancer. European Journal Of Cancer 2015, 51: s319. DOI: 10.1016/s0959-8049(16)30906-6.
- Matutino A, Mak M, Takahashi T, Bitton R, Nakazato D, Guimaraes R, Gabrielli F, da Conceiçãao Vasconcelos K, Carvalho H, Castro-Junior G. 3052 Prophylactic cranial irradiation for extensive stage small cell lung cancer. European Journal Of Cancer 2015, 51: s613. DOI: 10.1016/s0959-8049(16)31694-x.
- Protasio B, Matutino A, Lage L, De Santana I, Ramos R, Caires-Lima R, Caires I, Riechelmann R, Saragiotto D, Sabbaga J, Hoff P. Safety and efficacy of adjuvant modified FLOX for patients (pts) with stage III colorectal cancer (CRC) treated in the community. Journal Of Clinical Oncology 2015, 33: 760-760. DOI: 10.1200/jco.2015.33.3_suppl.760.
- Vilas-Boas A, Nascimento-Carvalho C, Matutino A, Barreto B, Silva C, Braga D, Oliveira F, Nogueira G, Oliveira Í, Lorgetto I, Costa I, Araripe J, Vieira J, Neiva L, Santana M, Nobre-Bastos M, Santos P, Câmara S, Carneiro S, Sirmos U, Araújo V, Silva C, Vilas-Boas C, Gantois D, Azevedo F, Maia J, Pirajá L, Jesus P, Fonseca T, Fontoura M, Xavier-Souza G, Araújo-Neto C, Andrade S, Brim R, Noblat L, Barral A, Cardoso M. Comparison of oral amoxicillin given thrice or twice daily to children between 2 and 59 months old with non-severe pneumonia: a randomized controlled trial—authors' response. Journal Of Antimicrobial Chemotherapy 2014, 70: 636-638. PMID: 25362570, DOI: 10.1093/jac/dku440.
- Isaacsson P, Teixeira M, Scaranti M, Matutino A, Negrao M, Fraile N, Souza K, Yen C, Pinheiro G, Hoff P, G.C.. 1391P Acute Infusional Reactions to Chemotherapy in an Outpatient Unit: Experience from 21,394 Treatment Cycles in Brazil. Annals Of Oncology 2014, 25: iv487. DOI: 10.1093/annonc/mdu353.5.
- Vilas-Boas A, Fontoura M, Xavier-Souza G, Araújo-Neto C, Andrade S, Brim R, Noblat L, Barral A, Cardoso M, Nascimento-Carvalho C, Matutino A, Barreto B, Silva C, Braga D, Oliveira F, Nogueira G, Oliveira Í, Lorgetto I, Costa I, Araripe J, Vieira J, Neiva L, Santana M, Nobre-Bastos M, Santos P, Câmara S, Carneiro S, Sirmos U, Araújo V, Silva C, Vilas-Boas C, Gantois D, Azevedo F, Maia J, Pirajá L, Jesus P, Fonseca T, Vilar T. Comparison of oral amoxicillin given thrice or twice daily to children between 2 and 59 months old with non-severe pneumonia: a randomized controlled trial. Journal Of Antimicrobial Chemotherapy 2014, 69: 1954-1959. PMID: 24648506, DOI: 10.1093/jac/dku070.
- Fontoura M, Matutino A, Silva C, Santana M, Nobre-Bastos M, Oliveira F, Barreto B, Araújo-Neto C, Andrade S, Brim R, Cardoso M, Nascimento-Carvalho C, Pneumopac-Efficacy Study Group. Differences in evolution of children with non-severe acute lower respiratory tract infection with and without radiographically diagnosed pneumonia. Indian Pediatrics 2012, 49: 363-369. PMID: 22080618, DOI: 10.1007/s13312-012-0085-6.
- Clinical failure among children with nonsevere community-acquired pneumonia treated with amoxicillinFontoura M, Araújo-Neto C, Andrade S, Brim R, Matutino A, Silva C, Santana M, Nobre-Bastos M, Oliveira F, Barreto B, Santos P, Noblat L, Cardoso M, Nascimento-Carvalho C, Group T. Clinical failure among children with nonsevere community-acquired pneumonia treated with amoxicillin. Expert Opinion On Pharmacotherapy 2010, 11: 1451-1458. PMID: 20408745, DOI: 10.1517/14656561003777034.
Departments and Programs
Locations
- Smilow Cancer Hospital at Yale New Haven35 Park StreetNew Haven, CT 06511
Titles
- Assistant Professor of Medicine (Medical Oncology)
Education & Training
- Medical Oncology FellowYale School of Medicine (2023)
- Internal Medicine ResidentUniversity of Connecticut (2021)
- Breast Cancer FellowUniversity of Calgary (2018)
- Medical Oncology FellowUniversidade de São Paulo (2016)
- Internal Medicine ResidentUniversidade de São Paulo (2013)
- MDUniversidade Federal da Bahia (2010)
Languages Spoken
- English
- Português (Portuguese)
Additional Information
Honors & Recognitions
- Robert A. Winn Diversity in Clinical Trials Career Development Award: American Association of Cancer Research (2023)
- Young Investigator Award: American Society of Clinical Oncology (ASCO) (2023)
Publications
- Foldi J, Kahn A, Silber A, Qing T, Reisenbichler E, Fischbach N, Persico J, Adelson K, Katoch A, Chagpar A, Park T, Blanchard A, Blenman K, Rimm DL, Pusztai L. Clinical Outcomes and Immune Markers by Race in a Phase I/II Clinical Trial of Durvalumab Concomitant with Neoadjuvant Chemotherapy in Early-Stage TNBC. Clinical Cancer Research 2022, 28: 3720-3728. PMID: 35903931, PMCID: PMC9444984, DOI: 10.1158/1078-0432.ccr-22-0862.
- Silva S, Pereira A, Marta G, de Barros Lima K, de Freitas T, Matutino A, de Azevedo Souza M, de Azevedo R, de Viveiros P, da Silva Lima J, Filassi J, de Andrade Carvalho H, Piato J, Mano M. Clinical impact of adjuvant radiation therapy delay after neoadjuvant chemotherapy in locally advanced breast cancer. The Breast 2017, 38: 39-44. PMID: 29223797, DOI: 10.1016/j.breast.2017.11.012.
- Shan NL, Kahn A, Pusztai L. Intratumour heterogeneity, from hypothesis to the clinic. British Journal Of Cancer 2022, 128: 459-460. PMID: 36216884, PMCID: PMC9938204, DOI: 10.1038/s41416-022-02008-w.
- Matutino A, Amaro C, Verma S. CDK4/6 inhibitors in breast cancer: beyond hormone receptor-positive HER2-negative disease. Therapeutic Advances In Medical Oncology 2018, 10: 1758835918818346. PMID: 30619511, PMCID: PMC6299331, DOI: 10.1177/1758835918818346.
- Matutino A, Lewis J, Verma S, Taylor A, Huber S, Chen G. The impact of age in the quality of life of patients diagnosed with breast cancer after curative treatment. Journal Of Clinical Oncology 2018, 36: 67-67. DOI: 10.1200/jco.2018.36.7_suppl.67.
- Kahn AM, Blenman KRM, Sonis ST, Lustberg MB. Strategies to mitigate the toxicity of cancer therapeutics. 2022, 155: 215-244. PMID: 35779875, DOI: 10.1016/bs.acr.2022.02.006.
- Matutino A, Pereira A, Kornaga E, Lupichuk S, Verma S. Comparison of clinical characteristics and survival of metastatic breast cancer patients in United States according to insurance status as compared to outcomes in Canada. Journal Of Clinical Oncology 2018, 36: e18617-e18617. DOI: 10.1200/jco.2018.36.15_suppl.e18617.
- Kahn A, Golestani R, Harigopal M, Pusztai L. Intratumor spatial heterogeneity in programmed death-ligand 1 (PD-L1) protein expression in early-stage breast cancer. Breast Cancer Research And Treatment 2023, 201: 289-298. PMID: 37378695, DOI: 10.1007/s10549-023-06977-1.
- Shalaby K, Kahn A, Silver ES, Kim MJ, Balakumaran K, Kim AS. Outcomes of acute pulmonary embolism in hospitalized patients with cancer. BMC Pulm Med 2022, 22: 11. PMID: 34986814, DOI: 10.1186/s12890-021-01808-9.
- Savard MF, Kornaga EN, Kahn AM, Lupichuk S. Survival in Women with De Novo Metastatic Breast Cancer: A Comparison of Real-World Evidence from a Publicly-Funded Canadian Province and the United States by Insurance Status. Curr Oncol 2022, 29: 383-391. PMID: 35049708, DOI: 10.3390/curroncol29010034.
- Lima G, Kahn A, Sama S, Savage J. Aseptic Meningitis as an Immune-Related Adverse Event after Pembrolizumab. Case Rep Oncol Med 2019, 2019: 7183747. PMID: 31781445, DOI: 10.1155/2019/7183747.
- Matutino A, Pereira A, Kornaga E, Lopes G, Bebb D, Verma S. Clinical characteristics and survival of lung cancer patients according to insurance status prior to and post implementation of the Affordable Care Act. Journal Of Clinical Oncology 2018, 36: e18607-e18607. DOI: 10.1200/jco.2018.36.15_suppl.e18607.
- Kornaga E, Matutino A, Pereira A, Verma S, Lupichuk S. Abstract P2-08-13: Survival in women with de novo metastatic breast cancer: Comparison of real-world evidence from publicly-funded Canadian province and the United States by insurance status. Cancer Research 2019, 79: p2-08-13-p2-08-13. DOI: 10.1158/1538-7445.sabcs18-p2-08-13.
- Matutino A, Kornaga E, Dean M, Pereira A, Bebb G. 40P Comparison of clinical characteristics and survival of lung cancer patients in a Canadian province and in the United States according to insurance status. Journal Of Thoracic Oncology 2018, 13: s22-s23. DOI: 10.1016/s1556-0864(18)30320-4.
- Matutino A, Mak M, Takahashi T, Bitton R, Nakazato D, Fraile N, Guimarães R, Gabrielli F, Vasconcelos K, de A. Carvalho H, de Castro G. Prophylactic Cranial Irradiation for Extensive-Stage Small-Cell Lung Cancer: A Retrospective Analysis. Journal Of Global Oncology 2017, 4: jgo.17.00059. PMID: 30241202, PMCID: PMC6181177, DOI: 10.1200/jgo.17.00059.
- Protásio B, Matutino A, Lage L, Santana I, Ramos R, Sabbaga J, Capareli F, Saragiotto D, Riechelmann R, Hoff P. Safety and Efficacy of a Modified FLOX Adjuvant Regimen for Patients With Stage III Colorectal Cancer Treated in the Community. Clinical Colorectal Cancer 2016, 16: 65-72. PMID: 27515842, DOI: 10.1016/j.clcc.2016.07.001.
- Silva A, Linck R, Lima J, Matutino A, Silva S, Vicentini M, Felizola M, Gagliato D, Hoff P, Mano M. Metaplastic breast cancer: A single-institution experience. Journal Of Clinical Oncology 2016, 34: e12575-e12575. DOI: 10.1200/jco.2016.34.15_suppl.e12575.
- Fraile N, Toloi D, Kurimori C, Matutino A, Codima A, Camargo V, Feher O, Munhoz R. Successful Intravascular Correction of Intratumoral Pseudoaneurysm by Erosion of the Aorta in a Patient with Thoracic Giant Cell Tumor of Bone Responding to Denosumab. Case Reports In Oncological Medicine 2015, 2015: 626741. PMID: 26600960, PMCID: PMC4639671, DOI: 10.1155/2015/626741.
- Vaisberg V, Vilas Boas M, Stephan B, Matutino A, Lima J, Mano M. Câncer de mama: efeito prognóstico da resposta patológica completa após quimioterapia neoadjuvante. Revista De Medicina 2015, 94: 31-31. DOI: 10.11606/issn.1679-9836.v94isupl.p31-31.
- Matutino A, Lima J, Silva S, Boas M, Stephan B, Van Vairsberg V, Fraile N, Barroso-Sousa R, Mano M. 1959 Neoadjuvant chemotherapy for elderly breast cancer patients. European Journal Of Cancer 2015, 51: s319. DOI: 10.1016/s0959-8049(16)30907-8.
- Lima J, Matutino A, Silva S, Silva-Junior A, Boas M, Stephan B, Van Vairsberg V, Pereira A, Barroso-Sousa R, Mano M. 1958 Correlation between body mass index and pathologic complete response after neoadjuvant chemotherapy for locally advanced breast cancer. European Journal Of Cancer 2015, 51: s319. DOI: 10.1016/s0959-8049(16)30906-6.
- Matutino A, Mak M, Takahashi T, Bitton R, Nakazato D, Guimaraes R, Gabrielli F, da Conceiçãao Vasconcelos K, Carvalho H, Castro-Junior G. 3052 Prophylactic cranial irradiation for extensive stage small cell lung cancer. European Journal Of Cancer 2015, 51: s613. DOI: 10.1016/s0959-8049(16)31694-x.
- Protasio B, Matutino A, Lage L, De Santana I, Ramos R, Caires-Lima R, Caires I, Riechelmann R, Saragiotto D, Sabbaga J, Hoff P. Safety and efficacy of adjuvant modified FLOX for patients (pts) with stage III colorectal cancer (CRC) treated in the community. Journal Of Clinical Oncology 2015, 33: 760-760. DOI: 10.1200/jco.2015.33.3_suppl.760.
- Vilas-Boas A, Nascimento-Carvalho C, Matutino A, Barreto B, Silva C, Braga D, Oliveira F, Nogueira G, Oliveira Í, Lorgetto I, Costa I, Araripe J, Vieira J, Neiva L, Santana M, Nobre-Bastos M, Santos P, Câmara S, Carneiro S, Sirmos U, Araújo V, Silva C, Vilas-Boas C, Gantois D, Azevedo F, Maia J, Pirajá L, Jesus P, Fonseca T, Fontoura M, Xavier-Souza G, Araújo-Neto C, Andrade S, Brim R, Noblat L, Barral A, Cardoso M. Comparison of oral amoxicillin given thrice or twice daily to children between 2 and 59 months old with non-severe pneumonia: a randomized controlled trial—authors' response. Journal Of Antimicrobial Chemotherapy 2014, 70: 636-638. PMID: 25362570, DOI: 10.1093/jac/dku440.
- Isaacsson P, Teixeira M, Scaranti M, Matutino A, Negrao M, Fraile N, Souza K, Yen C, Pinheiro G, Hoff P, G.C.. 1391P Acute Infusional Reactions to Chemotherapy in an Outpatient Unit: Experience from 21,394 Treatment Cycles in Brazil. Annals Of Oncology 2014, 25: iv487. DOI: 10.1093/annonc/mdu353.5.
- Vilas-Boas A, Fontoura M, Xavier-Souza G, Araújo-Neto C, Andrade S, Brim R, Noblat L, Barral A, Cardoso M, Nascimento-Carvalho C, Matutino A, Barreto B, Silva C, Braga D, Oliveira F, Nogueira G, Oliveira Í, Lorgetto I, Costa I, Araripe J, Vieira J, Neiva L, Santana M, Nobre-Bastos M, Santos P, Câmara S, Carneiro S, Sirmos U, Araújo V, Silva C, Vilas-Boas C, Gantois D, Azevedo F, Maia J, Pirajá L, Jesus P, Fonseca T, Vilar T. Comparison of oral amoxicillin given thrice or twice daily to children between 2 and 59 months old with non-severe pneumonia: a randomized controlled trial. Journal Of Antimicrobial Chemotherapy 2014, 69: 1954-1959. PMID: 24648506, DOI: 10.1093/jac/dku070.
- Fontoura M, Matutino A, Silva C, Santana M, Nobre-Bastos M, Oliveira F, Barreto B, Araújo-Neto C, Andrade S, Brim R, Cardoso M, Nascimento-Carvalho C, Pneumopac-Efficacy Study Group. Differences in evolution of children with non-severe acute lower respiratory tract infection with and without radiographically diagnosed pneumonia. Indian Pediatrics 2012, 49: 363-369. PMID: 22080618, DOI: 10.1007/s13312-012-0085-6.
- Clinical failure among children with nonsevere community-acquired pneumonia treated with amoxicillinFontoura M, Araújo-Neto C, Andrade S, Brim R, Matutino A, Silva C, Santana M, Nobre-Bastos M, Oliveira F, Barreto B, Santos P, Noblat L, Cardoso M, Nascimento-Carvalho C, Group T. Clinical failure among children with nonsevere community-acquired pneumonia treated with amoxicillin. Expert Opinion On Pharmacotherapy 2010, 11: 1451-1458. PMID: 20408745, DOI: 10.1517/14656561003777034.
Departments and Programs
Locations
- Smilow Cancer Hospital at Yale New Haven35 Park StreetNew Haven, CT 06511
- Smilow Cancer Hospital at Yale New Haven35 Park StreetNew Haven, CT 06511